You are here

Our Company

New Haven Pharmaceuticals, founded in 2008, leverages innovative technology developed by Yale University and is focused primarily on cardiovascular disease. The Company received FDA approval for DURLAZA®, the first extended release prescription 24-hour aspirin is now available by prescription throughout the United States.

The Company's development programs include Durlaza follow-on products and DURLAZA for gastroesophageal reflux disease.

The Company's innovative approach—emphasizing collaboration and problem-solving—means that New Haven Pharmaceuticals can capitalize on novel technologies and develop drugs quickly and safely so that physicians can prescribe and offer new and improved treatment options for their patients. By combining the extensive industry experience and expertise of the New Haven's management team with some of the most highly-acclaimed researchers and institutions in the world, the Company is dedicated to continually looking for opportunities to expand its development programs.

The Company's current partnerships with Yale University include:

John P. Geibel, DSc, MD, MSc, AGAF
Professor of Surgery (Gastrointestinal) and of Cellular and Molecular Physiology
Vice Chair, Surgery
Director, Surgical Research
Yale School of Medicine
American Gastroenterological Association Fellow

William C. Sessa PhD
Alfred Gilman Professor of Pharmacology and Professor of Medicine (Cardiology)
Vice Chairman, Pharmacology
Director, Vascular Biology & Therapeutics Program
Yale School of Medicine

New Haven Pharmaceuticals has recently launched DURLAZA and intends to expand the Company and its network of partnerships to develop, market and sell additional products, once regulatory approvals are obtained.